Welcome to our dedicated page for Forte Biosciences news (Ticker: FBRX), a resource for investors and traders seeking the latest updates and insights on Forte Biosciences stock.
Forte Biosciences, Inc. reports developments tied to FB102, its proprietary anti-CD122 monoclonal antibody therapeutic candidate for autoimmune and autoimmune-related diseases. Recurring updates cover clinical development in celiac disease, non-segmental vitiligo and alopecia areata, including regulatory designations such as Fast Track status in celiac disease.
Company news also includes quarterly and annual financial results, research and development spending tied to FB102, public financing activity, investor meeting participation and Nasdaq-required disclosures for equity inducement awards under its 2020 Inducement Equity Incentive Plan.
Forte Biosciences (NASDAQ:FBRX) granted equity inducement awards under Nasdaq Listing Rule 5635(c)(4) to a new non-executive employee. The grant includes options to purchase 50,000 shares and 50,000 restricted stock units, both vesting over four years, subject to continuous employment.
Forte Biosciences (NASDAQ:FBRX) reported Q1 2026 results and announced that FB102 received FDA Fast Track designation for celiac disease. FB102 phase 2 celiac topline data are expected in 2026, with phase 1b vitiligo readout shortly and alopecia areata data in 2026.
Q1 2026 research and development expenses were $20.5 million, general and administrative expenses were $2.0 million, and net loss per share was $(1.24). Forte ended the quarter with $58.2 million in cash and later raised $172.5 million gross in an April 2026 equity offering.
Forte Biosciences (Nasdaq: FBRX) priced a public offering of 5,709,936 common shares at $26.27 per share, with underwriters granted a 30-day option for up to 856,490 additional shares. Gross proceeds are expected to be approximately $150 million.
The offering is expected to close on or about April 10, 2026. Forte said net proceeds will fund working capital, clinical development of its product candidate, and other research activities.
Forte Biosciences (Nasdaq: FBRX) announced a proposed underwritten public offering of its common stock on April 8, 2026. Forte said it expects to grant underwriters a 30-day option to buy up to an additional 15% of the offered shares. All shares are being offered by the company and proceeds are intended for working capital, clinical development of its product candidate, and general corporate purposes. The offering is subject to market conditions and will be made pursuant to an effective Form S-3 registration statement; a preliminary prospectus supplement will be filed with the SEC.
Forte Biosciences (NASDAQ: FBRX) reported full-year 2025 results and a clinical update for FB102. R&D spending rose to $58.2M driven by Phase 2 celiac and multiple Phase 1b trials. Cash and equivalents were $77.0M at year-end with 12.9M shares outstanding.
The company expects multiple FB102 topline readouts in 2026, including Phase 2 celiac results and Phase 1b readouts in vitiligo and alopecia areata.
Forte Biosciences (NASDAQ: FBRX) announced inducement equity option awards totaling 25,000 shares to new non-executive employees, granted under the company’s 2020 Inducement Equity Incentive Plan. The options vest over four years: 25% after one year and the remaining 75% monthly over the next 36 months, subject to continuous employment.
The grants were approved by the Compensation Committee in accordance with NASDAQ Listing Rule 5635(c)(4) as material inducements for new hires.
Forte Biosciences (NASDAQ: FBRX) announced inducement equity awards for new non‑executive employees under Nasdaq Listing Rule 5635(c)(4). The company granted options to purchase an aggregate 100,000 shares of common stock under the 2020 Inducement Equity Incentive Plan.
The options vest over four years: 25% after one year and the remaining 75% in approximately equal monthly installments over the next 36 months, subject to continued employment and the related award agreements.
Forte Biosciences (NASDAQ: FBRX) announced management presentations at three investor conferences in February–March 2026. CEO Paul Wagner, PhD will present at the Guggenheim Emerging Outlook: Biotech Summit on Feb 11 at 8:30 am ET in New York, and at the TD Cowen Healthcare Conference on Mar 4 at 1:50 pm ET in Boston. Dr. Wagner will also attend the Barclays 28th Annual Global Healthcare Conference Mar 10–12 in Miami Beach.
Forte Biosciences (NASDAQ: FBRX) announced an inducement equity award dated December 22, 2025 under NASDAQ Listing Rule 5635(c)(4).
The Compensation Committee approved options to purchase 75,000 shares granted to a new non-executive employee as a material inducement to join the company, issued under the 2020 Inducement Equity Incentive Plan.
The options vest over four years: 25% at the one-year anniversary of employment and the remaining 75% in roughly equal monthly increments over the following 36 months, subject to continuous employment and the related award agreements.
Forte Biosciences (NASDAQ: FBRX) announced an inducement equity award under Nasdaq Listing Rule 5635(c)(4) dated November 24, 2025.
The Compensation Committee approved options to purchase 15,000 shares of common stock granted to a new non-executive employee as a material inducement to join the company. The options were issued under Forte’s 2020 Inducement Equity Incentive Plan and related award agreements.
The award vests over four years: 25% at the one-year anniversary of employment and the remaining 75% in approximately equal monthly installments over the following 36 months, subject to continued employment.